Fenwick Represents Neoleukin Therapeutics in $86.2 Million Public Offering

Fenwick & West represented Neoleukin Therapeutics, Inc (Nasdaq: NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, in its public offering of 10,263,750 shares of its common stock at a public offering price of $8.40 per share, which includes the exercise in full of the underwriters’ option to purchase 1,338,750 shares of common stock. The aggregate gross proceeds to Neoleukin, before deducting underwriting discounts and commissions and estimated offering expenses payable by Neoleukin, were approximately $86.2 million.

BofA Securities, Piper Jaffray and Guggenheim Securities acted as joint book-running managers for the offering. Canaccord Genuity acted as lead manager for the offering.

More information about the offering can be obtained from Neoleukin's announcement.

The Fenwick transaction team included corporate partners Effie Toshav and Robert Freedman and associates Julia Forbess, Ryan Mitteness, Chelsea Anderson, Ivan Au and Adam Conway.